Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/reversal of atherosclerosis with aggressive lipid lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada

Circulation

Volumn 112, Issue 9, 2005, Pages 1296-1300

  Austin, Peter C ^a,b   Mamdani, Muhammad M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Cholesterol; Drugs; Lipids; Pharmacology; Trials

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CANADA; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DRUG MARKETING; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TIME SERIES ANALYSIS;

AGED; CORONARY ARTERIOSCLEROSIS; DRUG UTILIZATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFECTION; MYOCARDIAL INFARCTION; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY;

EID: 24644489081     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.531582     Document Type: Article

References (22)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA. 2002;288:2981-2997.
2. Austin PC, Mamdani MM, Tu K, Zwarenstein M. Trends in use of antihypertensive medication in Ontario, Canada following publication of the ALLHAT Study. JAMA. 2004;291:44-45.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321-333.
4. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Trends in use of estrogen replacement therapy in Ontario, Canada following publication of the Women's Health Initiative Study. JAMA. 2003;289:3241-3242.
5. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
7. Sacks FM. High-intensity statin treatment for coronary heart disease. JAMA. 2004;291:1132-1134.
8. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
9. Pindyck RS, Rubinfeld DL. Econometric Models and Economic Forecasts. 4th ed. New York, NY: Irwin McGraw-Hill; 1998: chap. 15.
10. Helfenstein U. Box-Jenkins modelling in medical research. Stat Methods Med Res. 1996;5:3-22.
11. Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. J Am Stat Assoc. 1979;74:427-31.
12. Ljung GM, Box GEP. On a measure of lack of fit in time series models. Biometrika. 1978;65:297-303.
13. Fontanarosa PB, Flanagin A. Prepublication release of medical research. JAMA. 2000;284:2927-2929.
14. Kassirer JP, Angell M. Prepublication release of journal articles. N Engl J Med. 1997;337:1762-1763.
15. Gross CP, Steiner CL, Bass EB, Powe NR. Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy. JAMA. 2000;284:2886-2893.
16. Lamas GA, Pfeffer MA, Ham P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241-247.
17. Juurlink D, Mamdani MM, Lee DS, Austin PC, Laupacis A, Kopp A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation study. N Engl J Med. 2004;351:543-551.
18. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004;292:1983-1988.
19. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
20. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. Impact of clinical trial results on national trends in α-blocker prescribing, 1996-2002. JAMA. 2004;291:54-62.
21. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med. 2003;115:467-472.
22. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. Canadian Med Assoc J. 2003;168:553-557.